Clinical Trial Update: Sulforaphane to Reduce Symptoms of Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sulforaphane for reducing symptoms in schizophrenia and schizoaffective disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Sulforaphane (sulforaphane)

Snippet

Sponsor: Sheppard Pratt Health System | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2021-07-27